Atlas Trials

Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC)

Clinical trial NCT07241793 · RECRUITING

Trial details

NCT number
NCT07241793
Sponsor
Sun Yat-sen University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Urothelial CarcinomaAdvanced Urothelial CarcinomaUrothelial Carcinoma Recurrent
Start date
2025-11-20
Primary completion
2028-07-01
Enrollment
96

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.